Natasha Pinheiro, NP
Adult Health · Bronx, NYNPI 1649794744
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $831, 3.7 times the $223 reported in 2021.
Across 19 payments — averaging $100.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$375
- Bayer$364
- Incyte Corporation$349
- Exelixis Inc.$230
- Pfizer$202
- Deciphera Pharmaceuticals Inc.$129
- plus $252 from 3 others
What the payments were for
- Food & beverage$1,82196%
- Education$804%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $375 |
| Bayer | 4 | $364 |
| Incyte Corporation | 4 | $349 |
| Exelixis Inc. | 2 | $230 |
| Pfizer | 2 | $202 |
| Deciphera Pharmaceuticals Inc. | 1 | $129 |
| Puma Biotechnology, Inc. | 1 | $128 |
| E.r. Squibb & Sons, L.L.C. | 1 | $117 |
| Genentech USA, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,901 in reported general payments places this provider in the 80th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LonsurfTrifluridine/Tipiracil Hcl | 15 | $262,789 |
| Ursodiol | 13 | $1,468 |
| Ondansetron Hcl | 16 | $1,222 |
Paid to pharmacies, not to this prescriber.
Other adult health in Bronx
- Rachael StacomBronx$29K
- Robert PintauroBronx$21K
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Mary CiechoskiBuffalo$200K
- Jennifer FioriniGlens Falls$151K
- Katelyn McCormackAmherst$131K
- Maria Gigante-BaggettEast Syracuse$92K
- Jane PattersonRochester$66K
- Alyson HartyNew York$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.